Текагинлимаб

Rec. INN (наименование, зарегистрированное ВОЗ)

2253891-70-0

immunoglobulin G1-kappa, anti-[Homo sapiens CD40 (tumor necrosis factor receptor superfamily member 5, TNFRSF5, p50)] and anti-[Homo sapiens TNFRSF9 (tumor necrosis factor receptor (TNFR) superfamily member 9, 4-1BB, T cell antigen ILA, CD137)], humanized monoclonal antibody, bispecific;
gamma1 heavy chain humanized anti-CD40 (1-451) [VH anti-CD40 (Homo sapiens IGHV1-46*01 (85.7%) -(IGHD) -IGHJ4*01 (92.9%), CDR-IMGT [8.8.15] (26-33.51-58.97-111)) (1-122) -Homo sapiens IGHG1*03, G1m3, nG1m1, G1v41 CH2 F1.3, E1.2 (CH1 R120 (219) (123-220), hinge 1-15 (221-235), CH2 L1.3>F (239), L1.2>E (240), D27>A (270) (236-345), CH3 E12 (361), M14 (363), F85.1>L (410) (346-450), CHS K>del (451)) (123-451)], (225-214')-disulfide with kappa light chain humanized anti-CD40 (1'-214') [V-KAPPA anti-CD40 (Homo sapiens IGKV1-33*01 (88.4%) -IGKJ4*01 (100%), CDR-IMGT [6.3.9] (27-32.50-52.89-97)) (1'-107') -Homo sapiens IGKC*01 (100%), Km3 A45.1 (153), V101 (191) (108'-214')];
gamma1 heavy chain humanized anti-TNFRSF9 (1''-446'') [VH anti-TNFRSF9 (Homo sapiens IGHV3-49*04 (86.0%) -(IGHD) -IGHJ2*01 (92.9%) R120>Q (109), CDR-IMGT [8.7.11] (26-33.51-57.96-106)) (1''-117'') -Homo sapiens IGHG1*03, G1m3, nG1m1, G1v41 CH2 F1.3, E1.2 (CH1 R120 (214) (118''-215''), hinge 1-15 (216''-230''), CH2 L1.3>F (234), L1.2>E (235), D27>A (265) (231''-340''), CH3 E12 (356), M14 (358), K88>R (409) (341''-445''), CHS K>del (446)) (118''-446'')], (220''-217''')-disulfide with kappa light chain humanized anti-TNFRSF9 (1'''-217''') [V-KAPPA anti-TNFRSF9 (Homo sapiens IGKV1-33*01 (85.7%) -IGKJ1*01 (90.0%) Q120>G (103), CDR-IMGT [6.3.12] (27-32.50-52.89-100)) (1'''-110''') -Homo sapiens IGKC*01 (100%), Km3 A45.1 (156), V101 (194) (111'''-217''')]; dimer (231-226'':234-229'')-bisdisulfide, produced in Chinese hamster ovary (CHO) cells, glycoform alfa

Поделиться этой страницей